# Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Canonical URL: https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital
Ticker: ALZN
Company: Alzamend Neuro
Source: Alzamend Neuro
Published: 2026-04-07 12:00 EST
Original Source URL: https://ir.alzamend.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-04-07 12:00 EST — [Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital](https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital) — Source: Alzamend Neuro
- 2026-03-26 12:00 EST — [Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions](https://biopharmsignal.com/news/ALZN/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions) — Source: Alzamend Neuro
- 2026-03-16 12:00 EST — [Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital](https://biopharmsignal.com/news/ALZN/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-patients-with-bipolar-disorder-in-collaboration-with-massachusetts-general-hospital) — Source: Alzamend Neuro
- 2025-11-19 13:00 EST — [Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital](https://biopharmsignal.com/news/ALZN/alzamend-neuro-announces-completion-of-clinical-portion-of-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-conducted-at-massachusetts-general-hospital) — Source: Alzamend Neuro
- 2025-07-28 12:00 EST — [Alzamend Neuro to Present at the 2025 Military Health System Research Symposium](https://biopharmsignal.com/news/ALZN/alzamend-neuro-to-present-at-the-2025-military-health-system-research-symposium) — Source: Alzamend Neuro
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)